Urinary melatonin and risk of ovarian cancer

Cancer Causes and Control

Volumn 26, Issue 10, 2015, Pages 1501-1506

  Poole, Elizabeth M ^a   Schernhammer, Eva ^a,b   Mills, Leigha ^c   Hankinson, Susan E ^a,b,d   Tworoger, Shelley S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Circadian rhythm; Melatonin; Ovarian cancer

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; CREATININE; MELATONIN; 6-SULFATOXYMELATONIN;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MICTURITION; OVARY CANCER; PRIORITY JOURNAL; SHIFT WORKER; SLEEP PATTERN; SLEEP TIME; URINALYSIS; URINE LEVEL; ANALOGS AND DERIVATIVES; CIRCADIAN RHYTHM; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; RISK FACTOR; STATISTICAL MODEL; URINE; VERY ELDERLY; WORK SCHEDULE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; HUMANS; LOGISTIC MODELS; MELATONIN; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; RISK FACTORS; WORK SCHEDULE TOLERANCE;

EID: 84941424499     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0640-2     Document Type: Article

References (29)

1. Straif K, Baan R, Grosse Y et al (2007) Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 8:1065–1066
2. Poole EM, Schernhammer ES, Tworoger SS (2011) Rotating night shift work and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 20:934–938
3. Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2013) Nightshift work and risk of ovarian cancer. Occup Environ Med 70:231–237
4. Carter BD, Diver WR, Hildebrand JS, Patel AV, Gapstur SM (2014) Circadian disruption and fatal ovarian cancer. Am J Prev Med 46:S34–S41
5. Viswanathan AN, Schernhammer ES (2009) Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett 281:1–7
6. Anisimov VN (2006) Light pollution, reproductive function and cancer risk. Neuro Endocrinol Lett. 27:35–52
7. Haus EL, Smolensky MH (2013) Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev 17:273–284
8. Treeck O, Haldar C, Ortmann O (2006) Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 15:231–235
9. Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP (2011) Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 5:109–123
10. Futagami M, Sato S, Sakamoto T, Yokoyama Y, Saito Y (2001) Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells. Gynecol Oncol 82:544–549
11. Shellard SA, Whelan RD, Hill BT (1989) Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br J Cancer 60:288–290
12. Bartsch H, Buchberger A, Franz H et al (2000) Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci 67:2953–2960
13. Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E (1999) The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 26:129–136
14. Papazisis KT, Kouretas D, Geromichalos GD et al (1998) Effects of melatonin on proliferation of cancer cell lines. J Pineal Res 25:211–218
15. Chuffa LG, Fioruci-Fontanelli BA, Mendes LO et al (2013) Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. PLoS ONE 8:e81676
16. Moore CB, Siopes TD (2004) Spontaneous ovarian adenocarcinoma in the domestic turkey breeder hen (Meleagris gallopavo): effects of photoperiod and melatonin. Neuro Endocrinol Lett. 25:94–101
17. Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J (2006) Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis. Toxicology 228:333–343
18. Voordouw BC, Euser R, Verdonk RE et al (1992) Melatonin and melatonin–progestin combinations alter pituitary–ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 74:108–117
19. Karasek M, Kowalski AJ, Zylinska K (2000) Serum melatonin circadian profile in women suffering from the genital tract cancers. Neuro Endocrinol Lett. 21:109–113
20. Schernhammer ES, Hankinson SE (2005) Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 97:1084–1087
21. Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172
22. Wang XS, Tipper S, Appleby PN, Allen NE, Key TJ, Travis RC (2014) First-morning urinary melatonin and breast cancer risk in the Guernsey Study. Am J Epidemiol 179:584–593
23. Brown SB, Hankinson SE, Eliassen AH et al (2015) Urinary melatonin concentration and the risk of breast cancer in Nurses’ Health Study II. Am J Epidemiol 181:155–162
24. Schernhammer ES, Hankinson SE (2009) Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomarkers Prev. 18:74–79
25. Cos S, Gonzalez A, Guezmes A et al (2006) Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118:274–278
26. Bondi CD, Alonso-Gonzalez C, Clafshenkel WP et al (2014) The effect of estradiol, progesterone, and melatonin on estrous cycling and ovarian aromatase expression in intact female mice. Eur J Obstet Gynecol Reprod Biol 174:80–85
27. del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S (2004) Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279:38294–38302
28. Ciucci A, Zannoni GF, Travaglia D, Petrillo M, Scambia G, Gallo D (2014) Prognostic significance of the estrogen receptor beta (ERbeta) isoforms ERbeta1, ERbeta2, and ERbeta5 in advanced serous ovarian cancer. Gynecol Oncol 132:351–359
29. Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE (2004) Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 13:936–943